Drug trial for top parasitic killer of the Americas

According to results of the first-ever Phase 2 clinical trial in Bolivia, the drug candidate E1224 showed good safety and was effective at clearing the parasite causing Chagas disease, but had little to no sustained efficacy one year after treatment. On the other hand, standard therapy, benznidazole, was effective long term but continued to be associated with side effects. The results point to alternative dosing regimens and possible combination therapies to improve patient care.

Read the whole article on Science Daily

More from Science Daily